199 related articles for article (PubMed ID: 24655881)
1. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
[TBL] [Abstract][Full Text] [Related]
2. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
Woltering EA; Voros BA; Beyer DT; Wang YZ; Thiagarajan R; Ryan P; Wright A; Ramirez RA; Ricks MJ; Boudreaux JP
J Am Coll Surg; 2017 Apr; 224(4):434-447. PubMed ID: 28088602
[TBL] [Abstract][Full Text] [Related]
3. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors.
Cives M; Anaya DA; Soares H; Coppola D; Strosberg J
J Natl Cancer Inst; 2018 Mar; 110(3):282-289. PubMed ID: 29741649
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
6. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
8. Outcome of surgery for ileojejunal neuroendocrine tumors.
Habbe N; Fendrich V; Heverhagen A; Ramaswamy A; Bartsch DK
Surg Today; 2013 Oct; 43(10):1168-74. PubMed ID: 23143168
[TBL] [Abstract][Full Text] [Related]
9. Surgery for metastatic neuroendocrine tumors with occult primaries.
Bartlett EK; Roses RE; Gupta M; Shah PK; Shah KK; Zaheer S; Wachtel H; Kelz RR; Karakousis GC; Fraker DL
J Surg Res; 2013 Sep; 184(1):221-7. PubMed ID: 23643298
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.
Panzuto F; Campana D; Fazio N; Brizzi MP; Boninsegna L; Nori F; Di Meglio G; Capurso G; Scarpa A; Dogliotti L; De Braud F; Tomassetti P; Delle Fave G; Falconi M
Neuroendocrinology; 2012; 96(1):32-40. PubMed ID: 22205326
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.
Wonn SM; Limbach KE; Pommier SJ; Ratzlaff AN; Leon EJ; McCully BH; Pommier RF
Surgery; 2021 Jan; 169(1):168-174. PubMed ID: 32473829
[TBL] [Abstract][Full Text] [Related]
12. Multifocality in Small Bowel Neuroendocrine Tumors.
Gangi A; Siegel E; Barmparas G; Lo S; Jamil LH; Hendifar A; Nissen NN; Wolin EM; Amersi F
J Gastrointest Surg; 2018 Feb; 22(2):303-309. PubMed ID: 29119527
[TBL] [Abstract][Full Text] [Related]
13. Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.
Le Roux C; Lombard-Bohas C; Delmas C; Dominguez-Tinajero S; Ruszniewski P; Samalin E; Raoul JL; Renard P; Baudin E; Robaskiewicz M; Mitry E; Cadiot G;
Dig Liver Dis; 2011 Oct; 43(10):828-33. PubMed ID: 21641888
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of lymphatic mapping for midgut neuroendocrine patients undergoing cytoreductive surgery.
Wang YZ; Carrasquillo JP; McCord E; Vidrine R; Lobo ML; Zamin SA; Boudreaux P; Woltering E
Surgery; 2014 Dec; 156(6):1498-502; discussion 1502-3. PubMed ID: 25456941
[TBL] [Abstract][Full Text] [Related]
15. The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors.
Sun Y; Lohse C; Smyrk T; Hobday T; Kroneman T; Zhang L
Am J Surg Pathol; 2018 Feb; 42(2):247-255. PubMed ID: 29016403
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.
Dabaja BS; Suki D; Pro B; Bonnen M; Ajani J
Cancer; 2004 Aug; 101(3):518-26. PubMed ID: 15274064
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of two-stage hepatectomy for bilobar liver metastases.
Bowers KA; O'Reilly D; Bond-Smith GE; Hutchins RR
Am J Surg; 2012 Jun; 203(6):691-7. PubMed ID: 22154136
[TBL] [Abstract][Full Text] [Related]
19. Discussion.
J Am Coll Surg; 2014 Apr; 218(4):844-5. PubMed ID: 24655882
[No Abstract] [Full Text] [Related]
20. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.
Strosberg J; Gardner N; Kvols L
Neuroendocrinology; 2009; 89(4):471-6. PubMed ID: 19174605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
